Your browser doesn't support javascript.
loading
Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation.
Di Ianni, Mauro; Liberatore, Carmine; Santoro, Nicole; Ranalli, Paola; Guardalupi, Francesco; Corradi, Giulia; Villanova, Ida; Di Francesco, Barbara; Lattanzio, Stefano; Passeri, Cecilia; Lanuti, Paola; Accorsi, Patrizia.
Afiliação
  • Di Ianni M; Hematology Unit, Pescara Hospital, 65124 Pescara, Italy.
  • Liberatore C; Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Santoro N; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, 66100 Chieti, Italy.
  • Ranalli P; Hematology Unit, Pescara Hospital, 65124 Pescara, Italy.
  • Guardalupi F; Hematology Unit, Pescara Hospital, 65124 Pescara, Italy.
  • Corradi G; Hematology Unit, Pescara Hospital, 65124 Pescara, Italy.
  • Villanova I; Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Di Francesco B; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, 66100 Chieti, Italy.
  • Lattanzio S; Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Passeri C; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, 66100 Chieti, Italy.
  • Lanuti P; Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Accorsi P; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, 66100 Chieti, Italy.
Cells ; 13(2)2024 01 11.
Article em En | MEDLINE | ID: mdl-38247827
ABSTRACT
GvHD still remains, despite the continuous improvement of transplantation platforms, a fearful complication of transplantation from allogeneic donors. Being able to separate GvHD from GvL represents the greatest challenge in the allogeneic transplant setting. This may be possible through continuous improvement of cell therapy techniques. In this review, current cell therapies are taken into consideration, which are based on the use of TCR alpha/beta depletion, CD45RA depletion, T regulatory cell enrichment, NK-cell-based immunotherapies, and suicide gene therapies in order to prevent GvHD and maximally amplify the GvL effect in the setting of haploidentical transplantation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article